Doctors injected a single tumor and watched cancer vanish from patients’ entire bodies, offering real hope against deadly diseases long ignored by overregulated bureaucracies.
Story Highlights
- Phase 1 trial of 2141-V11 antibody shrank tumors body-wide in 6 of 12 patients with metastatic cancers like melanoma and breast cancer.
- Two patients achieved complete remission—all detectable tumors disappeared, even those not injected.
- Intratumoral injection avoids severe toxicity of past therapies, enabling safe outpatient treatment.
- Ongoing trials expand to bladder, prostate, and glioblastoma cancers with nearly 200 patients.
Breakthrough Trial Results
Researchers at Rockefeller University tested 2141-V11, a redesigned CD40 agonist antibody, in a phase 1 trial with 12 patients suffering metastatic cancers including melanoma, breast, and renal cell carcinoma. Doctors injected the antibody directly into one tumor.
In six patients, tumors shrank across the body, including sites never touched by the drug. Two patients saw complete remission where every detectable tumor vanished. This systemic effect stemmed from immune activation forming tertiary lymphoid structures that mimicked lymph nodes in tumors.
Breakthroughs like this are why sustained investment in biomedical science matters.
In an early trial, injecting immunotherapy into one tumor triggered immune responses across the body – with 50% of patients responding and some complete remissions.
Science saves lives. pic.twitter.com/V26f705tou
— Dr. Catharine Young (@DrCatharineY) March 18, 2026
Overcoming Past Failures
Jeffrey Ravetch led decades of work at Rockefeller’s Leonard Wagner Laboratory to refine CD40 agonists. Earlier intravenous versions caused severe toxicity by harming healthy tissues. The team engineered 2141-V11 for localized potency via intratumoral delivery.
This shift concentrated effects on tumors while sparing the body. Juan Osorio, first author and Memorial Sloan Kettering oncologist, analyzed how immune cells like dendritic, T, and B cells migrated to uninjected sites. Results published March 16, 2026, in Cancer Cell confirmed safety with only mild side effects.
Expert Insights on Immune Power
Ravetch noted a single thigh injection eradicated melanoma on a patient’s leg and foot. Osorio observed tumors filling with immune cells, resembling lymph nodes, even in distant locations. This transformation turned immunosuppressive “cold” tumors into immune hubs.
Unlike systemic drugs, 2141-V11 activated body-wide responses without dangerous side effects. Experts like UCLA’s Ribas highlighted immunotherapy’s role in boosting melanoma survival from 16% to 35% over 25 years, aligning with this advance.
The 50% response rate in phase 1 prioritized patients with high baseline T-cell clonality. Mild toxicity supports outpatient use, cutting costs compared to intravenous therapies. Trial patients with aggressive melanoma and breast cancer now live cancer-free, restoring hope to families battling these killers.
Expanding Trials and Future Impact
Memorial Sloan Kettering and Duke University now run phase 1/2 trials with nearly 200 patients targeting bladder, prostate, and glioblastoma cancers. Researchers seek biomarkers to predict responders and exclude non-responders. No new toxicity emerged.
Long-term, tertiary lymphoid structures could redefine treatment for solid tumors resistant to prior immunotherapies like CAR-T, which succeeded in blood cancers but struggled here. Reduced costs and scalability pressure pharmaceutical companies to adopt intratumoral methods.
This aligns with 2026 forecasts for personalized combinations, complementing advances like KAIST’s macrophage reprogramming and UCLA’s CAR-NKT cells.
New Cancer Immunotherapy Killed Whole Tumors
Researchers at Rockefeller University are reporting encouraging results from an early clinical trial of a redesigned cancer immunotherapy that is injected directly into tumors.
In the small study, six of 12 patients experienced…
— NENE'S MOMMA (@DebrulerTerri) March 18, 2026
Under President Trump’s leadership, innovation thrives without the heavy hand of government overreach that stifled past research. American ingenuity delivers real victories against cancer, prioritizing patients over endless regulations.
Families gain a fighting chance, echoing conservative values of self-reliance and cutting wasteful spending on failed approaches.
Sources:
Scientists inject one tumor and watch cancer vanish across the body
New cancer therapy hunts, destroys deadly tumors: major breakthrough study
CRI stats confirm immunotherapy trends
Experts forecast cancer research and treatment advances in 2026
